NCCM
ARIA

Nine Chapters Capital Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Nine Chapters Capital Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-39,400
Closed -$269K – 1050
2013
Q4 		$269K Buy
39,400
+7,600
+24% +$41K 0.03% 641
2013
Q3 		$585K Buy
+31,800
New +$617K 0.07% 383

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nine Chapters Capital Management's ARIA Position: Q1 2014 in Review

Nine Chapters Capital Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2014, closing a stake of 39,400 shares — an estimated $269K sold.

Nine Chapters Capital Management first reported a position in ARIA in Q3 2013 and held it in 2 quarters. The position peaked at $585K in Q3 2013. 171 funds tracked by Wall St. Rank hold ARIA as of Q1 2014.

  • Nine Chapters Capital Management reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2014 after selling out during the quarter.
  • Nine Chapters Capital Management sold 39,400 Ariad Pharmaceuticals Inc shares in Q1 2014, an estimated $269K.
  • Nine Chapters Capital Management first reported a position in Ariad Pharmaceuticals Inc in Q3 2013 and held it in 2 quarters.
  • Nine Chapters Capital Management's Ariad Pharmaceuticals Inc position peaked at $585K in Q3 2013.
  • 171 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2014.

Based on Nine Chapters Capital Management's 13F filing for Q1 2014, filed 15 May 2014.